Who makes Rheosorbilact®?

Rheosorbilact® is developed by Yuria-Pharm.

What development phase is Rheosorbilact® in?

Rheosorbilact® is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Rheosorbilact®

Yuria-Pharm · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Rheosorbilact®
Sponsor	Yuria-Pharm
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Burns (PHASE4)
Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Sepsis. (PHASE4)
Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Peritonitis (PHASE4)
Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Pneumonia (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Rheosorbilact® CI brief — competitive landscape report
Rheosorbilact® updates RSS · CI watch RSS
Yuria-Pharm portfolio CI